CRO Tigermed Consulting Revs Up Expansion With Fund Injection
This article was originally published in PharmAsia News
Executive Summary
Tigermed Consulting, one of China's largest CROs, has accepted the first round of capital injection from Qiming Venture Partners and will move into a rapid expansion stage. The funds will be used to improve the firm's high-quality service delivery system as well as recruit top talent worldwide to gear up for more international CRO projects. As one of the few CROs in China that can conduct global multicenter trials, Tigermed positions itself as a rival of multinational CRO Quintiles, with focus on talents rather than clients. The company boasts more than 50 percent of its employees are armed with a Master's or higher degree, and a staff turnover rate lower than 10 percent. Tigermed's business in 2007 outperformed its 100 percent growth the previous year. (Click here for more - Chinese Language)
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.